2012

December 2012

CSRC Annual Meeting 2012 & CRF Open Forum

November 2012

September 2012

July 2012

June 2012

May 2012

April 2012

February 2012

January 2012

CBI and Applied Clinical Trials 6th Annual Cardiovascular Risk Assessment Summit   > More Information about this event

Assess risk and avoid adverse CV events and post-marketing liabilities. Adverse cardiovascular events may pose a considerable threat during preclinical and clinical drug development, as well as in the post-marketing phase. As a result, the need for extensive cardiovascular risk assessment is increasingly recognized as critically important for successful drug development. CBI and Applied Clinical Trials 6th Annual Cardiovascular Risk Assessment Summit provides us with the opportunity to review the most effective strategies for understanding and assessing cardiovascular risk. Topics for discussion include: Guiding translational research into the clinic Identifying acceptable ranges of blood pressure and heart rate change Assessing automated algorithms in ECG analytics Minimizing post-marketing cardiovascular risk occurrence